SCHEMBL30954070

SCHEMBL30954070

CC(C)Oc1c(Cl)cc2c(c1C(=O)O)OCCN2C

nearest known ligand 0.35

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
S1PR1 P21453 2/20 0.34
CYP2C9 P11712 1/20 0.34
NOTUM Q6P988 1/20 0.34
DRD2 P14416 4/20 0.33
TP53 P04637 1/20 0.33
MAPT P10636 1/20 0.33
ALDH1A1 P00352 1/20 0.32
CPT2 P23786 2/20 0.32
CPT1A P50416 2/20 0.32
CPT1B Q92523 2/20 0.32
TDP1 Q9NUW8 1/20 0.32
BCL2 P10415 1/20 0.32
MCL1 Q07820 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27433312 1.00 S1PR1 (0.34) S1PR1CYP2C9NOTUMDRD2TP53
SCHEMBL27432464 0.86 KDM4E (0.43) NOTUMDRD2MAPTALDH1A1CPT2
SCHEMBL30954108 0.86 KDM4E (0.43) NOTUMDRD2MAPTALDH1A1CPT2
SCHEMBL27433483 0.80 TP53 (0.38) NOTUMDRD2TP53BCL2MCL1
SCHEMBL27432668 0.80 NOTUM (0.38) NOTUMDRD2TP53MAPTL3MBTL1
SCHEMBL30954119 0.80 NOTUM (0.38) NOTUMDRD2TP53MAPTL3MBTL1
SCHEMBL30954043 0.80 KDM4E (0.41) CYP2C9DRD2MAPTALDH1A1
SCHEMBL27432942 0.80 KDM4E (0.41) CYP2C9DRD2MAPTALDH1A1
SCHEMBL30954080 0.77 HSD17B10 (0.42) DRD2MAPTALDH1A1
SCHEMBL27432967 0.77 HSD17B10 (0.42) DRD2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP claimed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO claimed
EP-4630412-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-10-15 EP disclosed
WO-2024121130-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-06-13 WO disclosed